CONTRADICTING EVIDENCE: The analysis conducted in MM samples tested with ABT-199 agreed with previous clinical studies in MM, pointing to over-expression of Bcl-xl and Mcl1, as well as under-expression of Bim, Bcl-2, and NOXA in resistant samples.

...Karpas 620 CCND1 line was selected for its high Bcl-xL expression. Puma and Bim were found associated with both Bcl-2 and Bcl-xL in this cell line. After 6 h of ABT-199 treatment (25 nm), Puma/Bcl-2 and Bim/Bcl-2 complexes were disrupted in contrast to the Bcl-xL heterodimers that were not modified (Figure 1c)....Sensitivity to ABT-199 was significantly associated with higher expression of Bcl-2 (P=0.008) and tended to be associated with a lower Mcl-1 expression (P=0.09) (Supplementary Figure 2).